SCHEMBL14775341

SCHEMBL14775341

Clc1ccc(C(CCN2CCOCC2)N2CCCC2)cc1

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.74
SLC6A4 P31645 2/20 0.74
SLC6A3 Q01959 2/20 0.74
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 3/20 0.46
MAPT P10636 1/20 0.46
P2RX7 Q99572 3/20 0.44
ACHE P22303 1/20 0.43
RPS6KB1 P23443 1/20 0.43
HTR1A P08908 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
KCNH2 Q12809 1/20 0.43
CD274 Q9NZQ7 1/20 0.43
TP53 P04637 1/20 0.42
THRB P10828 1/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14775196 0.85 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3ALDH1A1
SCHEMBL16461842 0.75 DPP4 (0.55) SLC6A2SLC6A4SLC6A3ALDH1A1MAPT
SCHEMBL11489056 0.74 ALDH1A1 (0.46) SLC6A2SLC6A4SLC6A3KMT2AALDH1A1
SCHEMBL14775389 0.74 SLC6A2 (0.74) SLC6A2SLC6A4SLC6A3ALDH1A1MAPT
SCHEMBL9449932 0.74 ALDH1A1 (0.55) SLC6A2SLC6A4SLC6A3KMT2AALDH1A1
SCHEMBL4731651 0.74 TP53 (0.47) SLC6A2SLC6A4SLC6A3P2RX7TP53
SCHEMBL18824466 0.74 DPP4 (0.60) ALDH1A1MAPTP2RX7RPS6KB1TP53
SCHEMBL8276868 0.74 DPP4 (0.60) ALDH1A1MAPTP2RX7RPS6KB1TP53
SCHEMBL14775441 0.73 SLC6A2 (0.51) SLC6A2SLC6A4SLC6A3MAPTP2RX7
SCHEMBL28797889 0.72 KMT2A (0.50) SLC6A2SLC6A4SLC6A3KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570409-B1 ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT SHANGHAI INST PHARM INDUSTRY (CN) 2015-07-08 EP disclosed
US-8962621-B2 Aralkyl diamine derivatives and uses thereof as antidepressants SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2015-02-24 US disclosed
US-20130072488-A1 ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANTS SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2013-03-21 US disclosed
EP-2570409-A1 ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT Shanghai Institute of Pharmaceutical Industry (CN) 2013-03-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072488-A1 ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANTS MAOA, SLC6A2, MAOB SLC6A2 2/4885SLC6A4 5/4885SLC6A3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.